

2016

Perforated small intestine in a patient with T-cell lymphoma; a rare cause of peritonitis

Petrisor Banu

Carol Davila University, Department of Surgery, ptrbanu@gmail.com

Vlad D. Constantin

Carol Davila University, Department of Surgery

Florian Popa

Carol Davila University, Department of Surgery

Mihaela F. Nistor

St. Pantelimon Hospital, Department of Surgery

Follow this and additional works at: <http://scholar.valpo.edu/jmms>

 Part of the [Surgery Commons](#)

Recommended Citation

Banu, Petrisor; Constantin, Vlad D.; Popa, Florian; and Nistor, Mihaela F. (2016) "Perforated small intestine in a patient with T-cell lymphoma; a rare cause of peritonitis," *Journal of Mind and Medical Sciences*: Vol. 3 : Iss. 1 , Article 11.

Available at: <http://scholar.valpo.edu/jmms/vol3/iss1/11>

This Case Presentation is brought to you for free and open access by ValpoScholar. It has been accepted for inclusion in Journal of Mind and Medical Sciences by an authorized administrator of ValpoScholar. For more information, please contact a ValpoScholar staff member at scholar@valpo.edu.

Perforated small intestine in a patient with T-cell lymphoma; a rare cause of peritonitis

^{1,2}*Petrișor Banu*, ^{1,2}*Vlad D. Constantin*, ^{1,2}*Florian Popa*, ²*Mihaela F. Nistor*

¹Carol Davila University, Department of Surgery, ²St. Pantelimon Hospital, Department of Surgery

Abstract

The nontraumatic perforations of the small intestine are pathological entities with particular aspects in respect to diagnosis and treatment. These peculiarities derive from the nonspecific clinical expression of the peritonitis syndrome, and from the multitude of causes that might be the primary sources of the perforation: foreign bodies, inflammatory diseases, tumors, infectious diseases, etc. Accordingly, in most cases intestinal perforation is discovered only by laparotomy and the definitive diagnosis is available only after histopathologic examination. Small bowel malignancies are rare; among them, lymphomas rank third in frequency, being mostly B-cell non Hodgkin lymphomas. Only 10% of non-Hodgkin lymphomas are with T-cell.

We report the case of a 57 years' old woman with intestinal T-cell lymphoma, whose first clinical symptomatology was related to a complication represented by perforation of the small intestine. Laparotomy performed in emergency identified an ulcerative lesion with perforation in the jejunum, which required segmental enterectomy with anastomosis. The nonspecific clinical manifestations of intestinal lymphomas make from diagnosis a difficult procedure. Due to the fact that surgery does not have a definite place in the treatment of the small intestinal lymphomas (for cases complicated with perforation), and beyond the morbidity associated with the surgery performed in emergency conditions, prognosis of these patients is finally given by the possibility to control the systemic disease through adjuvant therapy.

Keywords: perforation, small intestine, T-cell lymphoma, peritonitis



Corresponding address: ptrbanu@gmail.com, Carol Davila University, Department of Surgery, Dionisie Lupu Street no. 37, Sect. 2 Bucharest, Romania (020022)

Introduction

The nontraumatic perforation of the small intestine is a rare pathological entity, which has particular aspects in respect to the clinical diagnosis and subsequent therapeutic conduct. These peculiarities derive especially from the difficulty of the preoperative diagnosis. In the majority of cases, the peritonitis syndrome imposes laparotomy which reveals the perforation of the intestine.

In addition, there are multitude of causes that might be the primary sources of the perforation: foreign bodies, inflammatory diseases, tumors, infectious diseases, etc., so that only the histopathologic examination would be conclusive for the establishment of a definitive therapeutic approach.

A variable geographical distribution can be observed when considering the etiology and incidence on age groups of the small intestine's perforations. The infectious causes, such as typhoid fever or tuberculosis predominate in tropical areas and in the developing countries, being often found at young aged patients, 20-30 years old, as opposed to the western countries where these cases appear much rarer and to older age groups, having as possible causes inflammatory diseases, tumors, radiotherapy, ingestion of foreign bodies or circulatory disorders (1- 4).

The diagnosis becomes a challenging task especially in circumstances in which the patient has no significant medical history, so that the diagnosis can be established only after surgery. Malignant tumors of the small intestine are in general rare (about 3% among digestive neoplasms, and 0.5% within all cancers), having poor clinical expression and a relatively difficult diagnosis with usual investigative methods (5).

Regarding their histology in last decades one can see a reversal of proportions in incidence of carcinoids as against adenocarcinomas while lymphomas ranks third in frequency after these with 17% of all malignant intestinal tumors (6). Non-Hodgkin's lymphomas are a heterogeneous group of neoplasms that can arise from B or T cells, progenitors or mature, or rarely from natural killer cells. 10 to 30 percent of patients with NHL have extra-nodal disease (7). The digestive tract represents the most frequent location of the non-Hodgkin extra-nodal lymphoma, about 36%, affecting the stomach, small intestine and colon, in order of frequency (8).

Case report

We report the case of a 57 years' old woman, with no significant medical history, admitted to the hospital for intense and diffuse abdominal pain, which emerged around 3 hour prior to the arrival at

the hospital. The patient described the debut of the pain in the upper abdomen, all of a sudden, like a „stabbing” feeling followed soon by the extending to the entire abdominal area.

Physical examination reveals fever 38⁰C, tachycardia and abdominal distention with tenderness to palpation and absence of bowel sounds.

Laboratory tests showed normal values for leucocytes (WBC- 8250 / μ L), neutrophil count not elevated (NEU- 6260/ μ L), low values for lymphocyte count(LYM- 1170/ μ L/ 14,22%), red blood cells (RBC) 3,62 /*10⁶ μ L, Hemoglobin (Hb) 10.2g/dL and HTC31,9%. It was also found decreased levels for sodium (130,5mmol/L) and potassium 3,23mmol/L. No other changes were found in laboratory tests on admission.

Plain X-ray film of the abdomen in upright position showed the presence of free air under the left diaphragm. Chest radiography did not identify changes in lungs or mediastinum. Based on clinical, imaging and laboratory data the presumptive diagnosis was peritonitis from perforated viscera and laparotomy was decided.

Midline vertical incision was made. The opening of the peritoneal cavity revealed small bowel content in peritoneum (*succus entericus*) and exploration showed a 3 millimeters perforation

situated at the anti-mesenteric border on a jejunum loop about 60 cm from the Treitz angle (Figure 1).




Figure 1.

The perforation adjacent area had a pale appearance and the mesentery exhibited multiple enlarged lymph nodes which were conglomerated especially at the root of the mesentery forming large lymphadenopathy masses at this level. The other intraperitoneal organs including liver and spleen had no changes macroscopically.

Small bowel resection and widely excision of adjacent mesentery was performed (Figure 2). The continuity was restored by end to end suturing anastomosis. Postoperative evolution was simple with no complications, and the patient was discharged 7 days after surgery.

Histopathological examination revealed:

Intestinal wall presenting a large ulceration about 1,5cm with perforation and diffuse transmural infiltration with large discoid cells

presenting oval and vesicular nuclei and eosinophilic cytoplasm in reduced amount; large number of areas of granulomatous inflammation.

Multiple tumor cells with hyperchromic and hypertrophic nuclei; tumoral cells with multiple nuclei and atypical mitosis. Mesenteric lymphnodes exhibited an altered architecture with sinusal hystiocytosis and irregular germinal centers. This appearance was suggestive of diffuse large cells intestinal lymphoma.

Immunohistochemical examination revealed:

CD3 diffuse positive in tumoral cells, CD2 positive in tumoral cells, CD 25 positive in rare tumoral cells, CD5 negative in tumoral cells, CD30 diffusely positive in tumoral cells cytoplasm and intense positive in some membranes; CD15 positive in numerous granulocytes and in rare tumoral cells with granule appearance near the nuclei; CD20 and CD79a negative in tumoral cells; ALK negative in tumoral cells.

Histopathological aspect and immunohistochemically tests are compatible with the diagnosis of Malign non Hodgkin lymphoma with T-cell type anaplastic large T-cell lymphoma ALK negative (ALCL, ALK). Testing for hepatitis B, hepatitis C and HIV serology were negative using the western blotting procedure, and absence of the specific anti-HTLV I/II antibodies was confirmed.



Figure 2.

Discussion

The primitive lymphomas of digestive tract remain rare entities, even though in the last decades a slight increase of their incidence (with percentage between 3 and 5) is reported. It is possible that this growth is due to the improvement of the immunohistochemical diagnosis which facilitates their diagnosis (8, 9).

The cellular tissue from which these malignancies arise is represented by the MALT (*mucosa associated lymphoid tissue*), designating a heterogeneous population of cells with immunologic role quartered at the level of digestive tract mucosa, playing an essential role as a protection barrier of body from a large variety of antigens.

The intestine hosts the lymphoid tissue in follicles, in Peyer's plaques, in lamina propria and

intraepithelial and the mesenteric lymph nodes make connection to the peripheral immune system.

The variety of the enteral lymphoid tissue's cells is very wide, but each phenotype can be individualized with cytogenetic and immunohistochemical techniques, so allowing the anatomic-clinical framing of the lymphomas, the indication of the treatment and the prognostic assessment.

Almost 90% of the gastrointestinal lymphomas derive from B lymphocytes and very few from T lymphocytes (10). They can be classified into three main categories: immunoproliferative small intestinal disease (IPSID), enteropathy-associated T cell lymphoma (EATL) which arises mostly in gluten-sensitive enteropathy and a third category comprising diffuse large B cell lymphoma, mantle cell lymphoma, Burkitt lymphoma and follicular lymphoma (11).

What causes for lymphomas is still unknown, but a set of conditions seem to favor their development: bacterial infections (e.g. *Helicobacter pylori* or *Helicobacter heilmannii*), viruses (HTLV-1 in human T-cell lymphoma virus, Epstein-Barr in Burkitt lymphoma), severe immune deficiencies (AIDS, Waldmann disease) or celiac disease (8, 12, 13).

Considering frequency order criteria, these locate predominant at stomach level, which sums 50-60% from primary digestive tract lymphomas; 20-50% affect the small intestine, especially the ileum. Very seldom, the primitive lymphomas can be found at the colon and rectum level (14- 17).

The symptoms are uncharacteristic for intestinal lymphomas, for example abdominal bloating and distension, colic abdominal pain, loss of appetite, nausea or may have the clinical expression of an acute complication like perforation, occlusion or bleeding. Other general signs also nonspecific are so called B symptoms (fever, weight loss and night sweats) which occurring in the context of a lymphoma get a prognosis value (18).

Classical methods of imaging diagnosis - barium studies and CT - can reveal tumors as intra- or extraluminal masses, polyps or parietal infiltration areas without offering data regarding the type of the lesion. On the other hand, endoscopy and particularly the "push and pull technique" with double balloon enteroscopy allows both biopsy sampling as well as execution of therapeutic maneuvers (19, 20).

The gastrointestinal localization can be secondary in non-Hodgkin lymphomas, appearing most frequently in the context of a widespread nodal disease and much rarely as a primary location.

In order to decide a diagnose to this last form it is necessary for the lesion to be limited to the intestine's level, the spleen and the liver not to be affected, no mediastinal and peripheral lymphadenopathy must be present, and the number of white blood cell count must be in normal limits (21, 22, 23).

The digestive lymphomas evaluation presumes a general balance that compulsory includes the exploration of renal function, hepatic function, serum electrolytes, blood test, lactic dehydrogenase, uric acid, chest x-ray, glycaemia and bone marrow biopsy. The evaluation is completed with the CT exam of the thorax, abdomen and pelvis. The anamnestic data and the complete physical exam can suggest particular etiologies that can be confirmed by specific investigations.

There is still not a consensus regarding the staging system for primary gastrointestinal lymphomas. The classical systems such as type Ann Arbor or Lugano seem to lend less, by omitting the disseminated forms or overlapping some distinctive clinical forms.

The Paris staging resorts to TNM type classification through which one can assess the degree of the tumor extends in the depth of the digestive wall, the contiguous lymph nodes involvement and the specific spread, contributing

in this way to offer the therapist an easier and more complex working instrument (24).

WHO (*World Health Organization*) scheme is the general frame of classification of lymphoid neoplasms unanimously accepted, wherewith different categories of diseases are defined by multidisciplinary approach including clinical, genetic, phenotypic and histological features (25).

The latter two classifications – TNM staging system and WHO scheme–meet the broadest consensus use for primary gastrointestinal lymphomas.

The gastrointestinal lymphomas treatment is multimodal and correlative with the histopathological type and the stage of the disease. Taking into consideration the large variety in lymphomas types, the therapeutically arsenal is complex too, but adaptable concurrently with a better understanding of pathogenesis and the molecular biology's progress (26).

The *Helicobacter pylori* infection is considered to be a predisposing factor to the development of the gastrointestinal tract lymphomas, even though it does not associate with a histopathological distinct type of these. The bacteria eradication treatment is part of the gastric lymphomas therapeutic strategies (27, 28).

The chemotherapy is administrated in cycles having types of cyclophosphamide-doxorubicin-vincristine combinations, or cyclophosphamide-vincristine to which it can be added prednisone or rituximab (29).

Radiotherapy finds its utility in forms localized at stomach, duodenum or rectum level, but enteral lymphomas may have less benefit from it taking into account that they are often multifocal (30, 31).

Only low-grade B-cell lymphoma of the small intestine can benefit from surgical resection as unique therapeutic method. In all the other cases, the role of surgery remains disputable, even though some studies show better survival rates of patients that were both having surgeries and following chemotherapy treatment, as compared to the ones who only had chemotherapy. The small number of patients included in these studies does not allow the establishment of definitive conclusions and the imposition of guidelines (32, 33).

Complications of gastrointestinal lymphomas are represented by obstruction, hemorrhage and perforation. For the small bowel as a particular location of lymphomas, perforation occurs in 9% of cases and it is associated with aggressive forms of the disease and chemotherapy. More than half of

perforations occur in the first 4-5 weeks of chemotherapy (34, 35).

Intraoperative appearance can be often in the form of an ulceration which can be macroscopically indistinguishable from other forms, and in this situation the histopathology examination becomes decisive in the establishment of the lesion's nature especially when the perforation appears in a case of a patient with no relevant case history.

In order to define the prognosis of these patients, several factors were taken into account but a real clinical significance have proved to have histological B type, symptoms, therapeutic modality, original site, LDH level and complication occurrences.

Worst prognosis is associated with high-grade lymphoma and intestinal location (36).

According to other studies, even though the perforation is a life-threatening complication, it seems to not influence the final prognostic of these subjects, which is ultimately given by the possibility to control the main disease (34).

Conclusions

Primitive gastrointestinal lymphomas represent a rare pathological entity and among

these, only 10% are T-cell type. The absence of specific signs and symptoms makes clinical diagnosis to be particularly difficult for these ones.

These malignancies benefit from a multimodal treatment in which surgery has not yet a definitive place. The role of surgery in the treatment of GI lymphomas remains a topic in debate and in literature has conflicting data regarding the therapeutic benefit of the surgical act. This is largely a consequence of the small number of cases included in reports so that clear guidelines cannot be traced yet.

The occurrence of a complication such as perforation compels emergency surgical treatment and lesion's resolving. Although perforation is a life threatening complication and beyond the morbidity of the surgical acts itself, the prognosis of these patients eventually is given by the ability to control the underlying disease.

References

1. Eustache JM, Kreis DJ. Typhoid perforation of the small intestine. *Arch Surg* 1983; 118: 1269–71.
2. Khanna AK, Misra MK. Typhoid perforation of the gut. *Postgrad Med J* 1984; 60: 523–5.
3. Leijonmarck CE, Fenyo G, Raf L. Nontraumatic perforation of the small intestine. *ActaChirScand* 1984;150: 405–411.
4. Kimchi NA, Broide E, Shapiro M, Scapa E. Non-traumatic perforation of the small intestine. Report of 13 cases and review of the literature. *Hepato-Gastroenterology* 2002; 49: 1017–22.
5. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. *CA Cancer J Clin.* 2015; 65(1): 5-29.
6. Bilimoria KY, Bentrem DJ, Wayne JD, Ko CY, Bennett CL, TalamontiMS. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. *Ann Surg.* 2009; 249(1): 63-71.
7. Anderson T, Chabner BA, Young RC, Berard CW, Garvin AJ, Simon RM, DeVita VT Jr. Malignant lymphoma. 1. The histology and staging of 473 patients at the National Cancer Institute. *Cancer* 1982; 50(12): 2699-707.
8. Abbott S, Nikolousis E, Badger I. Intestinal lymphoma--a review of the management of emergency presentations to the general surgeon. *Int J Colorectal Dis.* 2015; 30(2): 151-7.

9. Gurney KA, Cartwright RA, Gilman EA. Descriptive epidemiology of gastrointestinal non-Hodgkin's lymphoma in a population-based registry. *Br J Cancer* 1999; 79(11-12): 1929-34.
10. Ghimire P, Wu GY, Zhu L. Primary gastrointestinal lymphoma. *World Journal of Gastroenterology* 2011; 17(6): 697-707.
11. Mori M, Kobayashi Y, Maeshima AM, Gotoda T, Oda I, Kagami Y, Bennett S, Nomoto J, Azuma T, Yokoyama H, Maruyama D, Kim SW, Watanabe T, Matsuno Y, Tobinai K. The indolent course and high incidence of t(14;18) in primary duodenal follicular lymphoma, *Ann Oncol.* 2010; 21(7): 1500-5.
12. Ruskoné-Fourmestraux A, Rambaud J.C. Gastrointestinal lymphoma: prevention and treatment of early lesions. *Best Pract. Res. Clin. Gastroenterol.* 2001; 15(2): 337-354.
13. Stolte M, Bayerdorffer E, Morgner A, Alpen B, Wundisch T, Thiede C, Neubauer A. Helicobacter and gastric MALT lymphoma. *Gut.* 2002; 50(3): 19-24.
14. Herrmann R, Panahon AM, Barcos MP, Walsh D, Stutzman L. Gastrointestinal involvement in non-Hodgkin's lymphoma. *Cancer* 1980; 46(1): 215-22.
15. Ferreri AJ, Montalbán C. Primary diffuse large B cell lymphoma of the stomach. *Crit Rev Oncol Hematol.* 2007; 63: 65-71.
16. Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, Grothaus-Pinke B, Reinartz G, Brockmann J, Temmesfeld A, Schmitz R, Rube C, Probst A, Jaenke G, Bodenstein H, Junker A, Pott C, Schultze J, Heinecke A, Parwaresch R, Tiemann M. Primary gastrointestinal non-Hodgkin's lymphoma: I. anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. *J Clin Oncol.* 2001; 19(18): 3861-73.
17. Dionigi G, Annoni M, Rovera F, Boni L, Villa F, Castano P, Bianchi V, Dionigi R. Primary colorectal lymphomas: review of the literature. *Surg Oncol.* 2007; 16(1): S169-71.
18. Anderson T, Chabner BA, Young RC, Berard CW, Garvin AJ, Simon RM, DeVita VT Jr. Malignant lymphoma. 1. The histology and staging of 473 patients at the National Cancer Institute. *Cancer* 1982; 50(12): 2699-707.
19. Pennazio M. Small-intestinal pathology on capsule endoscopy: spectrum of vascular lesions. *Endoscopy* 2005; 37(9): 864-9.

20. Matsumoto T, Nakamura S, Esaki M, Yada S, Moriyama T, Yanai S, Hirahashi M, Yao T, Iida M. Double-Balloon Endoscopy Depicts Diminutive Small Bowel Lesions in Gastrointestinal Lymphom, *Dig Dis Sci.* 2010; 55(1): 158-165.
21. Dawson IM, Cornes JS, Morson BC. Primary malignant lymphoid tumours of the intestinal tract. Report of 37 cases with a study of factors influencing prognosis. *Br J Surg.* 1961; 49: 80–89.
22. Cooper MJ, Williamson RC. Enteric adenoma and adenocarcinoma, *World J Surg.* 1985; 9(6): 914-20.
23. Sweetenham JW, Mead GM, Wright DH, McKendrick JJ, Jones DH, Williams CJ, Whitehouse JM. Involvement of the ileocaecal region by non-Hodgkin's lymphoma in adults: clinical features and results of treatment. *Br J Cancer.* 1989; 60(3): 366-9.
24. Ruskoné-Fourmestraux A, Dragosics B, Morgner A, Wotherspoon A, de Jong D. Paris staging system for primary gastrointestinal lymphomas. *Gut.* 2003; 52(6): 912-913.
25. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. *Blood.* 2011; 117(19): 5019-5032.
26. Nakamura S, Matsumoto T. Gastrointestinal lymphoma: Recent advances in diagnosis and treatment. *Digestion* 2013; 87(3): 182-188.
27. Fischbach W, Goebeler-Kolve ME, Dragosics B, Greiner A, Stolte M. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive *Helicobacter pylori* eradication therapy: experience from a large prospective series. *Gut.* 2004; 53(1): 34- 7.
28. Hansen PB, Vogt KC, Skov RL, Pedersen-Bjergaard U, Jacobsen M, Ralfkiaer E. Primary gastrointestinal non-Hodgkin's lymphoma in adults: a population-based clinical and histopathologic study. *J Intern Med.* 1998; 244(1): 71-8.
29. Khosla D, Kumar R, Kapoor R , Kumar N, BeraA, Sharma SC. A retrospective analysis of clinicopathological characteristics, treatment, and outcome of 27 patients of primary intestinal lymphomas, *J Gastrointest Canc.* 2013; 44(4): 417–421.
30. Dickson BC, Serra S, Chetty R. Primary gastrointestinal tract lymphoma: diagnosis and

- management of common neoplasms. *Expert Rev Anticancer Ther.* 2006; 6: 1609–1628.
31. Ghimire P, Wu GY, Zhu L. Primary gastrointestinal lymphoma. *World Journal of Gastroenterology* 2011; 17(6): 697-707.
32. Chen JH, Ho CL, Chen YC, Chao TY, Kao WY. Clinicopathological analysis and prognostic factors of 11 patients with primary non-Hodgkin lymphoma of the small intestine in a single institute. *Oncol Lett.* 2014; 8(2): 876-880.
33. Ibrahim EM, Ezzat AA, El-Weshi AN, Martin JM, Khafaga YM, Al Rabih A, Ajarim DS, Al-Foudeh MO, Zucca E. Primary intestinal diffuse large B-cell non-Hodgkins lymphoma: clinical features, management, and prognosis of 66 patients. *Ann Oncol.* 2001; 12(1): 53–58.
34. Vaidya R, Habermann TM, Donohue JH, Ristow KM, Maurer MJ, Macon WR, Colgan JP, Inwards DJ, Ansell SM, Porrata LF, Micallef IN, Johnston PB, Markovic SN, Thompson CA, Nowakowski GS, Witzig TE. Bowel perforation in intestinal lymphoma: incidence and clinical features. *Ann Oncol* 2013; 24(9): 2439-2443.
35. Vaidya R, Habermann TM, Donohue JH, Ristow KM, Maurer MJ, Macon WR, Colgan JP, Inwards DJ, Ansell SM, Porrata LF, Micallef IN, Johnston PB, Markovic SN, Thompson CA, Nowakowski GS, Witzig TE. Bowel perforation in intestinal lymphoma: incidence and clinical features. *Ann Oncol.* 2013; 24(9): 2439-2443.
36. Li M, Zhang S, Gu F, Xiao W, Yao J, Chao K, Chen M, Li J, Zhong B. Clinicopathological characteristics and prognostic factors of primary gastrointestinal lymphoma: a 22-year experience from South China. *Int J Clin Exp Pathol.* 2014; 7(5): 2718–2728.